Cycle Patent-Cliff Exposure & CMS Drug Spending Portfolio
Cycle (US): 3 reconciled FDA prescription therapies, $23.9M 2024 CMS Part D & Medicaid spend, and $89,106 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2035-01-01 |
| 2024 CMS Total Public Spend | $23.9M |
| 2024 Medicare Part D Spend | $2.0M |
| 2024 Medicaid Spend | $22.0M |
| California HCAI SB 17 Filings | Specialty launch notice ($89,106 intro WAC) |